Henry Meds AI Market Strategy Report - TRT Clinics

Answer Capsule

Henry Meds holds meaningful AI presence in the TRT Clinics category but converts far less of that presence into recommendations than its visibility suggests. In September 2026, the brand appeared in 20.64% of qualified AI observations yet earned valid recommendation coverage of only 9.63%, and its 14.3-point decline since the July 2026 baseline was the largest of any tracked brand. The clearest win is a positive sentiment profile with no negative framing recorded. The clearest weakness is a collapsing top-three placement rate, now at 5.50%. The clearest opportunity is closing the gap between how often Henry Meds is mentioned and how often it is actually shortlisted.

Who This Report Is For

This report is for Henry Meds leadership, growth, and brand teams evaluating how the clinic is positioned in AI-generated recommendations across the TRT Clinics category, and for anyone responsible for demand generation in AI-led discovery.

Report Card

Executive Summary

Henry Meds is visible in AI answers but under-recommended relative to that visibility. The brand appeared in 45 of 218 qualified observations in September 2026, a raw mention presence rate of 20.64%, yet received valid recommendation credit in only 21 of those observations, a coverage rate of 9.63%. That gap between presence and recommendation is the central finding of this report.

The benchmark shows Henry Meds as the category's largest decliner against the July 2026 baseline. Valid recommendation coverage fell 14.3 points from 23.9% in July to 9.6% in September, a drop the LLM Authority Index flagged as beyond normal month-to-month variation. The decline ran across two consecutive months, with the steeper single-month move of 10.0 points occurring in August and a further 4.3-point decline in September.

Placement quality deteriorated alongside coverage. The top-three recommendation rate fell to 5.50% in September from 11.50% in July, and rank-one placements collapsed to a single observation, a rank-one rate of 0.46%. Valid recommendation counts fell from 50 in July to 29 in August to 21 in September.

Sentiment framing remains a relative strength. Henry Meds recorded 29 positive mentions, 16 neutral mentions, and zero negative mentions in September 2026, producing a net sentiment score of 0.6444. The brand is not being framed negatively; it is being framed less often as a recommendation.

The strongest platform signal for Henry Meds is Perplexity, where the brand captured a 42.11% share of AI opportunity despite a small observation base of six. The clearest platform gap is Gemini, where Henry Meds recorded zero presence across 20 observations, while competitors such as Maximus and Defy Medical captured 65.00% and 60.00% valid recommendation coverage respectively on that surface.

The clearest cluster gap is structural. All 218 qualified observations in September 2026 fell into the Brand Recommendation class. The benchmark's Pricing & Value and Multi-Brand Comparison clusters produced zero qualified observations, meaning the public series cannot yet show how Henry Meds performs when buyers explicitly compare clinics or weigh cost.

What Henry Meds Is Winning

Questions This Section Answers

• Where does Henry Meds actually convert AI mentions into recommendations?
• How clean is Henry Meds's sentiment profile compared with its recommendation performance?

Henry Meds holds a clean sentiment profile. Across 45 mentions in September 2026, the brand recorded 29 positive, 16 neutral, and zero negative classifications. No tracked competitor recorded a negative mention either, but Henry Meds maintained positive framing without any cautionary language attached.

The brand retains a narrow but real recommendation pocket on Perplexity. Henry Meds captured a 42.11% share of AI opportunity on that surface, the highest captured share of any platform for the brand, with one valid recommendation from a single mention. The sample is small, and the result should be read as directional rather than established.

Henry Meds also holds measurable presence on AI Mode and AI Overviews. On AI Mode, the brand appeared in 11 of 57 observations with a 10.53% valid recommendation coverage rate. On AI Overviews, it appeared in 25 of 94 observations with an 8.51% coverage rate. These are the two surfaces carrying the largest observation volume in the benchmark, and Henry Meds is present on both.

Beyond these points, the win column is thin. The brand's overall recommendation conversion, placement quality, and baseline trajectory all point downward.

Where Henry Meds Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why does Henry Meds get mentioned so often but recommended so rarely?
• Which competitors are displacing Henry Meds in top-three AI shortlists?
• Where does Henry Meds have zero presence while competitors capture recommendations?

The primary gap is recommendation conversion. Henry Meds appears in AI answers at more than twice the rate it gets recommended. A raw mention presence rate of 20.64% against a valid recommendation coverage of 9.63% means the brand is frequently referenced as context, comparison anchor, or background rather than as a shortlist option.

Competitor displacement is severe at the top of the category. Hone Health holds 42.66% valid recommendation coverage and a 33.94% top-three rate. Defy Medical holds 40.83% coverage and a 19.72% top-three rate. Maximus holds 27.52% coverage but the highest rank-one rate among leaders at 9.63%. Henry Meds sits fifth in the category at 9.63% coverage, roughly a quarter of the leader's rate.

The top-three gap is the sharpest displacement signal. Henry Meds holds a 5.50% top-three rate against Hone Health's 33.94%, Defy Medical's 19.72%, and Maximus's 20.64%. When AI systems build a shortlist, Henry Meds is being left off it far more often than its raw presence would suggest.

Platform coverage is uneven. Henry Meds recorded zero presence on Gemini across 20 observations, while Maximus captured 13 recommendations on that surface and Defy Medical captured 12. For Henry Meds, the Gemini absence is the clearest surface-level gap given the volume of observations there.

The brand's rank-one position has nearly disappeared. Henry Meds held a single rank-one placement in September 2026, a 0.46% rate, down from a 4.6% rank-one rate implied by earlier series data. Competitors Maximus and Hone Health held 21 and 18 rank-one placements respectively.

Biggest Opportunity

Questions This Section Answers

• What is the single clearest opportunity for Henry Meds in AI recommendations?
• Which prompts should Henry Meds investigate first to close the mention-to-recommendation gap?

The single clearest opportunity is converting existing mention presence into shortlist placement. Henry Meds already appears in roughly one in five qualified AI observations. The brand does not need to earn more mentions first; it needs those mentions to resolve into recommendations.

The mechanism sits in the recommendation-shaped answer layer. The benchmark's valid recommendation shortlist share fell to 55.5% in September 2026 from 64.6% in July, meaning a smaller share of answers are structured as usable shortlists across the category. For a brand with high presence and low conversion, that shift is both a risk and an opening: answers that mention Henry Meds without recommending it are the specific prompts where the brand's evidence layer is not doing enough work.

The highest-priority diagnostic is which prompt types now mention Henry Meds without recommending it, and which competitor captures the recommendation when Henry Meds drops out of the shortlist. That question is answerable only at the prompt level, not from the aggregate benchmark.

Competitive Landscape

Questions This Section Answers

• Where does Henry Meds rank against Hone Health, Defy Medical, and Maximus on top-three and rank-one rates?
• How does Henry Meds's average recommended rank compare with the category leaders?

Hone Health and Defy Medical hold the strongest recommendation-stage positions in the TRT Clinics category, with Maximus close behind on placement quality. Henry Meds sits in the middle of the tracked set, visible but under-recommended relative to its presence rate.

Average recommended rank covers rank-eligible recommendations only.

Henry Meds ranks fifth by top-three rate, behind Hone Health, Maximus, Defy Medical, and Marek Health. Its rank-one rate of 0.46% is tied with Fountain TRT and Low T Center near the bottom of the tracked set, and its average recommended rank of 3.25 places it behind the three leaders on placement quality as well.

Prompt Evidence

AI Mode / Brand Recommendation Prompt: "best testosterone replacement therapy" Result: Henry Meds appeared in the answer but was not placed in the top three recommendations, consistent with its 5.50% top-three rate.

AI Overviews / Brand Recommendation Prompt: "online doctors that prescribe testosterone" Result: Henry Meds was present in the response set with positive framing, contributing to its 8.51% valid recommendation coverage on this surface.

Perplexity / Brand Recommendation Prompt: "trt clinic" Result: Henry Meds received a valid recommendation with an average recommended rank of 2, one of the brand's strongest single placements in the September series.

Gemini / Brand Recommendation Prompt: "online testosterone therapy" Result: Henry Meds did not appear in the Gemini observation set, where competitors Maximus and Defy Medical captured 13 and 12 recommendations respectively.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map the specific prompts where Henry Meds is mentioned but not recommended, and identify which competitor captures the shortlist slot when the brand drops out.

Phase 2: Recommendation Readiness Plan Prioritize the prompt clusters and surfaces where conversion from mention to recommendation is weakest, starting with Gemini and the top-three placement gap.

Phase 3: Owned Answer Layer Buildout Strengthen the pages and structured content that AI systems retrieve when forming TRT clinic shortlists, focused on the attributes that drive recommendation rather than reference.

Phase 4: Citation / Authority Layer Development Build the public evidence layer that supports recommendation-stage answers, including the source types AI systems appear to synthesize from when ranking clinics.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track recommendation coverage, top-three rate, and rank-one rate month over month to confirm whether the conversion gap is closing.

Why This Matters

Questions This Section Answers

• What is the difference between being mentioned and being recommended for Henry Meds in AI answers?
• What does the gap between mention presence and recommendation coverage mean for Henry Meds entering buyer shortlists?

AI presence alone is not enough. Henry Meds is mentioned in roughly one in five qualified AI observations, but it is recommended in fewer than one in ten. For a buyer asking an AI system for the best TRT clinic, that difference determines whether Henry Meds enters the shortlist or becomes background context.

The next move is targeted correction of the prompt, page, and citation layers that shape recommendation-stage answers. The benchmark flags the movement; the mechanism sits one level deeper, in the specific queries where Henry Meds is visible but not chosen.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Henry Meds in September 2026: (29 × 1 + 16 × 0 + 0 × -1) / 45 = 0.6444.

This matters because unclassified mention counts are misleading. A brand can appear frequently in AI answers without ever being recommended, and a raw mention total treats a positive recommendation, a neutral reference, and a cautionary mention as equal. They are not equal.

Share of voice is a diagnostic metric, not a business KPI. Counting all mentions as wins is bad measurement. Henry Meds recorded zero negative mentions in September 2026, which is a genuine strength, but that strength sits alongside a recommendation conversion rate of 9.63%. Classified sentiment is required before interpreting AI visibility, and it must be read separately from recommendation coverage.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Henry Meds within the TRT Clinics category, drawing on the LLM Authority Index AI Market Discovery Index and the associated September 2026 metrics aggregation.
2. The reporting window is September 2026, with comparison points at the July 2026 baseline and the August 2026 intermediate measurement.
3. Six AI and search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. The September 2026 collection began with 800 prompt-surface observations and produced 218 qualified benchmark observations after qualification.
5. The competitor universe contains 10 tracked brands: BioTE, Craft Concierge, Defy Medical, Fountain TRT, Henry Meds, Hone Health, Low T Center, Marek Health, Maximus, and Renew Vitality.
6. Three public high-intent clusters were defined: Best TRT Clinics & Top Testosterone Therapy Providers (consideration), TRT Clinic Comparisons & Testosterone Therapy Alternatives (evaluation), and TRT Clinic Pricing, Cost & Affordability (decision).
7. All 218 qualified observations in September 2026 fell into the Brand Recommendation class. The Pricing & Value and Multi-Brand Comparison clusters produced zero qualified observations in the public series.
8. A mention is counted when a tracked brand appears in a qualified AI observation, regardless of whether it is recommended.
9. A valid recommendation is counted when a brand receives a clear, actionable recommendation with rank eligibility from 1 to 10. Neutral, cautionary, comparison-anchor, and listed-only mentions are not counted as valid recommendations.
10. Brand-level percentages use the 218 qualified observations as the public denominator, not the 800 raw prompt-surface observations.
11. Unique question count for September 2026 was 535 after de-duplication. The public version does not expose the full unique prompt list.
12. Small-count movement applies to several brands in this benchmark. Henry Meds operates on 21 valid recommendations, so a change of a few recommendations moves its percentages materially. Directional analysis identifies changes worth investigating; it does not by itself establish cause.

See Where AI Is Recommending Your Brand

The public benchmark shows where Henry Meds is winning and losing in AI-generated recommendations. A company-level AI visibility audit maps the specific prompts, surfaces, competitors, and evidence sources behind those movements, and isolates the queries where the brand is mentioned but not chosen.